.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Indian healthcare sector is witnessing a massive technological shift, particularly in how we treat complex diseases. Specifically, Bengaluru-based startup 4baseCare is driving this change through advanced genomic solutions. The company recently raised a total of ₹128 crore in funding. This fresh capital will help democratize precision oncology across emerging markets. Consequently, more patients will gain access to personalized, data-driven cancer therapies.
Currently, researchers concentrate most genomic datasets in the US and Europe. However, these datasets fail to represent diverse global populations. To solve this, 4baseCare is building population-specific genomic databases. Specifically, they target under-represented populations in India, the Middle East, Southeast Asia, and Latin America. Additionally, they plan to expand into 10 more countries over the next 18 months. Currently, they operate active labs in India, Dubai, Nepal, and the Philippines.
Earlier, clinics shipped cancer diagnostic samples from across India directly to Bengaluru. This process often delayed crucial treatment decisions. Therefore, 4baseCare is actively decentralizing its genomic testing infrastructure. The company is partnering with leading healthcare institutions to establish in-hospital labs. For instance, they have partnered with Max Healthcare, AIIMS Jammu, and Shankara Hospital. Consequently, doctors can now access advanced diagnostics much faster. This localized model improves turn-around times and fosters deeper research collaborations.
Alongside genomics, the company is scaling its proprietary AI platform called OncoTwin. This platform integrates multimodal datasets to assist clinical decision-making. Specifically, it combines genomic, pathology, radiology, and clinical records to create 'digital twins' of patients. As a result, oncologists receive real-world evidence of what worked for similar patients. This platform does not recommend direct treatments. Instead, it serves as an advanced clinical decision support tool. Ultimately, this leads to highly personalized and precise therapies.
In India, clinics report approximately 15 lakh new cancer cases annually. Unfortunately, doctors diagnose nearly 70% of these patients at advanced stages. At this point, systemic treatments like targeted therapies become critical. Genomic testing is vital to map these personalized remedies. However, high costs have historically limited patient access. To solve this, 4baseCare has lowered its testing prices significantly. They now price some offerings at one-fourth of the market rate. Furthermore, they hope to integrate these tests into public schemes like Ayushman Bharat.
Q1: What is OncoTwin and how does it assist cancer treatment?
OncoTwin is an AI-powered clinical decision support platform. It integrates genomic, pathology, radiology, and clinical data to create digital twins of patients. This allows oncologists to match patients with similar real-world treatment journeys and outcomes.
Q2: Why is 4baseCare expanding genomic testing beyond Indian metros?
The company aims to address gaps in population-relevant genomic data across tier 2 and tier 3 cities. By establishing in-hospital genomics labs, they reduce turn-around times and make advanced cancer diagnostics more affordable and accessible to diverse patients.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Bengaluru-based precision oncology startup 4baseCare has raised ₹128 crore in funding, co-led by growX Ventures and Infosys. The capital will be utilized to expand its genomics laboratory network globally, scale its OncoTwin AI platform, and democratize access to advanced cancer diagnostics in emerging markets.
last month
A parliamentary panel has urged the FSSAI to finalise front-of-pack nutrition labelling regulations without further delay. The committee stressed that simple, color-coded indicators for sugar and clear warning labels are vital to combat dietary non-communicable diseases and guide informed consumer choices.
3 days back
A comprehensive analysis of the NFHS-5 data regarding postpartum anemia in India, exploring the prevalence, severity, and the socioeconomic and regional factors contributing to this public health challenge for clinicians seeking to improve maternal health outcomes.
Last week
A study in Greece reveals that 46-80% of heatwave deaths are linked to climate change. This analysis explores the implications for public health and clinical practice, particularly for elderly and vulnerable populations facing rising global temperatures in regions like India.
2 weeks back
Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
last month
A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
3 days back
